CCCS Raises Concerns with OSIM’s Product Information Transparency and Pricing

CCCS Raises Concerns with OSIM’s Product Information Transparency and Pricing

13 February 2025

CCCS has raised concerns about certain business practices of OSIM International Pte. Ltd. (“OSIM”) related to product endorsement, product standards, suitability for specific consumers, and pricing. In response, OSIM has provided an undertaking to improve transparency in its product information and taken the following steps to address the concerns raised by CCCS:

a) Removed “Stanford Medicine” logo from its promotional materials;

c) Provided greater disclosure of product suitability information on its website and instructed its sales representatives to remind customers about product suitability before purchase;[7] and

d) Ensured that its promotions reflected actual discounts.

As part of the undertaking given to CCCS, OSIM also agreed to implement an internal compliance policy to ensure compliance with Singapore’s fair trading laws.

“CCCS combines rigorous enforcement with collaborative industry engagement to improve fair trading business practices. In this case, we acknowledge OSIM’s active response to address the concerns raised by CCCS and its commitment to improve its business practices. We encourage other businesses to review their practices to ensure that any representations they make are accurate, genuine, and include sufficient disclosure to reduce the risk of consumer disputes and enhance trust in the marketplace”, said CCCS’s Chief Executive, Mr. Alvin Koh.

Please refer to the media release for more details.